GlassScriptPhysician profile
Richard T David
NPI 1104821800
$1,631.70
in general payments reported to CMS, 2019-2025
23 companies · $22.85 in 2025
The $22.85 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $461 · 2020: $373 · 2021: $226 · 2022: $116 · 2023: $221 · 2024: $212 · 2025: $22.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $455.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $227.48 | 2019-2024 | |
| Amgen INC. | $217.09 | 2019-2022 | |
| Abbvie INC. | $191.89 | 2020-2022 | |
| Novo Nordisk INC | $170.15 | 2020-2025 | Ozempic, Rybelsus |
| Mylan Specialty L.P. | $101.26 | 2019-2021 | |
| Amarin Pharma, INC. | $96.86 | 2019-2020 | |
| Hologic Sales and Service, LLC | $88.14 | 2024 | Aptima |
| Novartis Pharmaceuticals Corporation | $87.86 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $66.94 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $66.17 | 2019 | |
| Organon LLC | $50.52 | 2022 | |
| Allergan, INC. | $36.28 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $28.86 | 2023 | Rexulti |
| Merck Sharp & Dohme LLC | $27.74 | 2019-2020 | |
| Gilead Sciences, INC. | $27.17 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $24.91 | 2023 | Keveyis |
| Abiomed | $24.74 | 2024 | Impella |
| Genentech USA, INC. | $20.94 | 2020 | |
| Insulet Corporation | $18.71 | 2024 | Omnipod |
| Glaxosmithkline, LLC. | $18.49 | 2023 | Trelegy Ellipta |
| Sunovion Pharmaceuticals INC. | $15.57 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.12 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $11.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard David listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.